DJ Pharma Secures $25 Million in Private Financing for Acquisition and Marketing Strategy

Strategic Insights -

DJ Pharma, Inc. has announced the successful completion of a private financing round, securing $25 million in funding to fuel its product acquisition and marketing strategy. The San Diego-based specialty pharmaceutical company will use the investment to expand its sales force and acquire additional patented or branded pharmaceutical products. DJ Pharma's sales force is currently promoting two prescription product lines, including Keftab(R) and Dura-Vent(R), and is expanding to 125 salespersons across the country.

Key Takeaways:

  • DJ Pharma has secured $25 million in private financing to fund its product acquisition and marketing strategy.
  • The company will use the investment to expand its sales force and acquire additional patented or branded pharmaceutical products.
  • DJ Pharma is currently promoting two prescription product lines, Keftab(R) and a family of cough-cold-allergy products, including Dura-Vent(R) and Rondec(R).
  • The company's sales force is expanding to 125 salespersons across the country.
  • William Blair Capital Partners led the investment round, which also included PPM America, Inc., Elan International Services, Ltd., and Dura Pharmaceuticals, Inc. (Dura).
  • Donaldson, Lufkin & Jenrette Securities Corporation acted as the financial advisor for DJ Pharma.
  • James W. Newman, CEO and President of DJ Pharma, stated that the company is excited about the strong group of investors and looks forward to ensuring the success of the company.

Statistics:

  • $25 million: The amount of private financing secured by DJ Pharma.
  • 125: The number of salespersons that DJ Pharma's sales force will expand to across the country.
  • 2: The number of prescription product lines being promoted by DJ Pharma, including Keftab(R) and a family of cough-cold-allergy products.
  • 2: The number of product line acquisitions made by DJ Pharma from Dura Pharmaceuticals.

Sources:

  • DJ Pharma, Inc. press release, January 26
  • PPM America, Inc. (no date)
  • Elan International Services, Ltd. (no date)
  • Dura Pharmaceuticals, Inc. (no date)
  • Donaldson, Lufkin & Jenrette Securities Corporation (no date)